ClinicalTrials.gg
RecruitingNCT06919822Updated Feb 19, 2026

SCAN Targeted Epidural Modulation for Parkinson's Disease

An interventional study of Personalized SCAN Targeted Epidural Modulation in Parkinson Disease, sponsored by Changping Laboratory. Recruiting at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Changping Laboratory · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Planned enrollment
204th of 211
3 · median 47
Started
2025
with 32 others
No phase
115 of 279
57 open now
Primary completion
2026-09
later than 55 of 134 live
Registered
204th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 204th largest by planned enrollment of the 211 interventional ones that give a count, is one of 33 that started in 2025, is one of 115 with no phase, reaches primary completion later than 55 of the 134 other live ones, and was the 204th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if epidural modulation targeting the Somato-Cognitive Action Network (SCAN) can improve motor symptoms in adults with idiopathic Parkinson's disease (PD). It will also evaluate the safety of this treatment. The main questions it aims to answer are:

  • Does epidural modulation targeting SCAN reduce motor symptoms (measured by MDS-UPDRS-III scores) in PD patients after 3 months?
  • Is SCAN targeted epidural modulation (STEM) a safe and tolerable treatment for PD, with minimal adverse effects?

Researchers will compare participants' baseline motor function to their post-treatment results to determine if STEM is effective.

Participants will:

  • First undergo non-invasive brain stimulation (iTBS) to test responsiveness.
  • If eligible, receive surgical implantation of STEM electrodes in the personalized SCAN target.
  • Complete follow-up visits for 12 months to monitor symptoms, side effects, and quality of life.
Read the detailed description

Background:

This is a prospective, open-label, single-center clinical trial investigating the efficacy and safety of personalized epidural modulation targeting the Somato-Cognitive Action Network (SCAN) in patients with idiopathic Parkinson's disease (PD). The study employs a two-stage intervention approach with comprehensive clinical and functional assessments. The study builds upon recent discoveries that the SCAN network shows preferential connectivity with PD-affected subcortical structures. By combining advanced neuroimaging for personalized target identification with staged therapeutic intervention, the trial aims to establish proof-of-concept for this novel neuromodulation approach. The design allows for initial non-invasive validation of target engagement through iTBS before proceeding to surgical implantation.

Study Design and Methodology:

The trial consists of two sequential stages:

- Screening and iTBS Intervention Stage (7 days) and a Washout Period (1-3 months): Eligible participants will first undergo intermittent theta-burst stimulation (iTBS) to their individualized SCAN target, identified through resting-state functional MRI and personalized-Brain-Functional-Sector (pBFS) mapping.

Participants demonstrating ≥30% improvement in motor symptoms proceed to a mandatory washout period.

Complete cessation of all neuromodulation therapies while maintaining stable PD medications.

- Surgical Intervention and Follow-up (12 months): Responsive patients undergo epidural electrode implantation over their predetermined SCAN target.

A scheduled12 months follow-up.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with idiopathic Parkinson's disease (PD) according to the revised clinical diagnostic criteria of the International Movement Disorder Society (MDS) (2015 version) or the Chinese Parkinson's Disease Diagnostic Criteria (2016 version).
  • Age between 40 and 75 years, with a minimum age of 40 years at the time of diagnosis.
  • Any gender, including both male and female patients.
  • Hoehn-Yahr staging between 2 and 4 (inclusive).
  • Disease duration of 5 years or more.
  • Responding effectively to levodopa-based drug therapy with a minimum of 30% improvement in the levodopa loading test.
  • Presence of motor fluctuations with or without anisocoria despite optimal drug treatment.
  • Stable on medication for at least the past 1 month prior to screening and surgery.
  • Ability to understand the trial and willingness to sign an form.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Parkinsonian superimposed syndrome or secondary Parkinson's disease.
  • Presence of intracranial structural variants or other abnormalities that may interfere with TMS or surgical treatment, as detected by MRI or CT.
  • Implantation of metallic medical devices such as deep brain stimulators, cochlear implants, vagus nerve stimulators, etc., which may affect MRI examination and TMS treatment.
  • to MRI scanning, including claustrophobia, tattoos, or magnetic metal-containing implants (to be confirmed with specialists).
  • History of comorbid epilepsy or having first-degree relatives with a history of epilepsy.
  • Receipt of other neuromodulation treatments (e.g., TMS, transcranial electrical stimulation, transcranial ultrasound stimulation) within the 1 months prior to enrollment.
  • Contraindications to neurosurgery, such as bleeding or coagulation disorders.
  • Presence of severe organic diseases, including heart failure, renal failure, or .
  • Cognitive impairment as indicated by score of 24 or below.
  • Significant speech impairment, hearing impairment, or visual impairment that limits cooperation with testing.
  • Severe depression (HAMD-17 score of 24 or above) or severe anxiety (HAMA score of 29 or above).
  • Diagnosed psychiatric disorders based on criteria or any psychological issues that may interfere with the study protocol.
  • Alcohol or substance abuse.
  • Active infections including virus (HBV), virus (HCV), syphilis, or (HIV) infection as determined by the investigator.
  • Any other medical abnormalities deemed by the investigator to be unsuitable for participation in the trial.
  • Inability to complete follow-up visits due to geographical or other reasons.
  • Women of childbearing age who are pregnant, breastfeeding, or intend to become pregnant during the trial.
  • Participation in other clinical trials concurrently.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (estimated)

Study arms

  • Experimental
    Personalized STEM Intervention Arm

    This experimental arm involves a comprehensive two-stage therapeutic intervention for Parkinson's disease patients: * Pre-surgical Screening Stage: * All participants first undergo non-invasive intermittent theta-burst stimulation (iTBS) targeting their individualized Somato-Cognitive Action Network (SCAN) region. * Surgical Intervention Stage (for iTBS responders): * Patients showing ≥30% improvement in motor symptoms proceed to epidural implantation of electrodes over the predetermined SCAN target.

    Device: Personalized SCAN Targeted Epidural Modulation

Interventions

  • DevicePersonalized SCAN Targeted Epidural Modulation

    * Stage 1: iTBS Intervention (7 days) and Washout Period (1-3 months) * All enrolled participants undergo: * Baseline clinical assessments * Structural and functional MRI with pBFS mapping * Resting motor threshold determination * Daily iTBS sessions targeting individualized SCAN coordinates: * Treatment duration: 7 consecutive days * Post-intervention evaluation at Day 7-14 * Mandatory observation window: * No neuromodulation therapies permitted * Stable PD medication regimen maintained * Monthly safety monitoring * Stage 2: Surgical Intervention and Follow-up (12 months) * Surgical Procedure: * Epidural electrode implantation * Pulse generator internalization * Epidural Modulation Stage: * Parameter optimization visits * Scheduled follow-ups at Months 1, 3, 6, 12

06

What researchers measure

Primary outcomes

  1. Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III motor scores at 3 months post-stimulation(medication "off" state)

    The change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) motor examination scores measured during the medication "off" state (after 12-hour overnight withdrawal of anti-Parkinson medications) from baseline to 3 months after initiating motor cortex stimulation. Higher scores indicate more severe motor impairment (range 0-132). A negative change indicates improvement.

    Time frame: Baseline to 3 months post-stimulation

Secondary outcomes

  1. Change in MDS-UPDRS-III scores (ON/OFF states) from baseline to 12 months

    Difference in Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) motor examination scores (range 0-132, higher=worse) between baseline and post-stimulation assessments during both medication ON (2 hours after levodopa dose) and OFF (after 12-hour withdrawal) states.

    Time frame: Baseline, 1-week, 1/3/6/12 months post-stimulation

  2. Change in daily OFF time duration (hours) from baseline

    Reduction in self-reported daily hours of OFF periods (time when Parkinson's medications are ineffective) as recorded in patient diaries, comparing baseline to post-stimulation timepoints.

    Time frame: Baseline, 1/3/6/12 months post-stimulation

  3. Change in daily ON time duration (hours) from baseline

    Increase in self-reported daily hours of good ON periods (medication effectiveness without troublesome dyskinesia) from baseline to follow-up assessments.

    Time frame: Baseline, 1/3/6/12 months post-stimulation

  4. Change in 39-item Parkinson's Disease Questionnaire summary index score from baseline

    Difference in 39-item Parkinson's Disease Questionnaire (PDQ-39) total score (range 0-100, higher=worse quality of life) between baseline and follow-up assessments.

    Time frame: Baseline, 1/3/6/12 months post-stimulation

  5. Change in Clinical Global Impression (CGI) score from baseline

    Improvement in clinician-rated CGI scale (range 1-7, higher=worse) assessing overall disease severity change since baseline.

    Time frame: Baseline, 1/3/6/12 months post-stimulation

  6. Change in levodopa equivalent daily dose (LEDD) from baseline

    Reduction in calculated total daily dopaminergic medication dosage (mg/day) while maintaining symptom control.

    Time frame: Baseline, 3/6/12 months post-stimulation

Other outcomes

  1. Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part I (MDS-UPDRS-I) scores from baseline

    Difference in MDS-UPDRS-I non-motor experiences of daily living scores (range 0-52, higher=worse) between baseline and post-stimulation assessments.

    Time frame: Baseline, 1/3/6/12 months post-stimulation

  2. Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part II (MDS-UPDRS-II) scores from baseline

    Difference in MDS-UPDRS-II non-motor experiences of daily living scores (range 0-52, higher=worse) between baseline and post-stimulation assessments.

    Time frame: Baseline, 1/3/6/12 months post-stimulation

  3. Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part IV (MDS-UPDRS-IV) scores from baseline

    Difference in MDS-UPDRS-IV motor complications scores (range 0-24, higher=worse) assessing dyskinesia and motor fluctuations.

    Time frame: Baseline, 1/3/6/12 months post-stimulation

  4. Change in Non-Motor Symptoms Scale (NMSS) score from baseline

    Difference in Non-Motor Symptoms Scale total score (range 0-360, higher=worse) evaluating frequency and severity of non-motor symptoms in Parkinson's disease.

    Time frame: Baseline, 1/3/6/12 months post-stimulation

  5. Change in Pittsburgh Sleep Quality Index (PSQI) score from baseline

    Difference in Pittsburgh Sleep Quality Index global score (range 0-21, higher=worse sleep quality) assessing sleep disturbances and patterns.

    Time frame: Baseline, 1/3/6/12 months post-stimulation

  6. Change in Hamilton Depression Rating Scale-17 (HAMD-17) score from baseline

    Difference in 17-item Hamilton Depression Rating Scale scores (range 0-52, higher=more severe depression) evaluating depressive symptoms.

    Time frame: Baseline, 1/3/6/12 months post-stimulation

  7. Change in Hamilton Anxiety Rating Scale (HAMA) score from baseline

    Difference in Hamilton Anxiety Rating Scale scores (range 0-56, higher=more severe anxiety) assessing anxiety symptoms.

    Time frame: Baseline, 1/3/6/12 months post-stimulation

  8. Change in Mini-Mental State Examination (MMSE) score from baseline

    Difference in Mini-Mental State Examination total score (range 0-30, higher=better cognitive function) assessing global cognitive status.

    Time frame: Baseline, 3/12 months post-stimulation

  9. Change in Montreal Cognitive Assessment (MoCA) score from baseline

    Difference in Montreal Cognitive Assessment total score (range 0-30, higher=better cognitive function) evaluating multiple cognitive domains.

    Time frame: Baseline, 3/12 months post-stimulation

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2026, 9 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 9 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2025
First posted
Apr 9, 2025
StartActual
Dec 8, 2025
Primary completionEst.
Sep 2026
CompletionEst.
May 2027
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06919822
Lead sponsor
Changping Laboratory
Collaborators
First Affiliated Hospital of Fujian Medical University
Responsible party
Sponsor
First posted
Apr 9, 2025
Start date
Dec 8, 2025
Primary completion
Sep 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Feb 19, 2026

Study contacts

Hesheng Liu, PhD
Contact
liuhesheng@cpl.ac.cn
+86 13263297367
Jianxun Ren, PhD
Contact
jianxun.ren@cpl.ac.cn
+86 18813001989
Hesheng Liu, PhD
study chair · Changping Laboratory

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion